* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co FCF Margin % Chart
For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Pharmaceuticals Holding Co FCF Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co (SHPMY) has a FCF Margin % of -2.25% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #49 out of 116 companies in the Medical Distribution industry, placing it in the top 42.2%.
Is Shanghai Pharmaceuticals Holding Co's FCF Margin % too high?
Shanghai Pharmaceuticals Holding Co's current FCF Margin % is -2.25%. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #49 out of 116 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's FCF Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #49 out of 116 companies for FCF Margin %. This puts Shanghai Pharmaceuticals Holding Co in the upper half of its industry. The industry median FCF Margin % is 1.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Distribution company?
The median FCF Margin % among Medical Distribution companies is 1.06, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. For the Medical Distribution industry, the median FCF Margin % is 1.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pharmaceuticals Holding Co's current FCF Margin % is -2.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co (SHPMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.50, compared to a current price of $7.34 — trading 22.7% below its estimated fair value. The current FCF Margin % is -2.25%. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMY), the current FCF Margin % is -2.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pharmaceuticals Holding Co (SHPMY) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued.
The current stock price of $7.34 is trading 22.7% below its estimated GF Value™ of $9.50.
GuruFocus considers Shanghai Pharmaceuticals Holding Co to be Modestly Undervalued.
Key valuation signals for SHPMY:
FCF Margin %: -2.25%
GF Value™: $9.50 vs. price of $7.34 (22.7% below fair value)
No single metric tells the full story. See the SHPMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pharmaceuticals Holding Co Business Description
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
79GF Score
Get the complete analysis for SHPMY
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPMY has been successfully added to your 
